The CEO of the Russian Direct Investment Fund (RDIF) said on Thursday that the country is looking to partner up with India for the mass production of the COVID-19 vaccine Sputnik V.
It is to be noted that Russia announced world's first COVID-19 vaccine, and it has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the RDIF.
"The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have," Dmitriev said.
We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India. We are planning to produce the vaccine in more than five countries and there is a very high demand from Asia, Latin America, Italy, and other parts of the world regarding the delivery of the vaccine," he added.
The vaccine consists of two shots that use different adenoviruses versions.
"The approach of the Gamaleya Institute with the vaccine, using two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has a clear advantage over the one-vector approach used by other developers," Gintsburg said.
As Russia announced the arrival of a new COVID-19 vaccine in the market, the declaration raised alarms in the scientific community as global health experts are finding it hard to trust the claims in the absence of full trial data.
According to a report by Reuters, immunologists and infectious disease experts say the step by Russia to claim the first spot in the global race to develop a vaccine against COVID-19 could be a "reckless" step.
The report quoted Francois Balloux, an expert at University College London`s Genetics Institute, who called it "a reckless and foolish decision".
Meanwhile, Germany also called into question the quality and safety of the coronavirus vaccine launched by Russia.
"There is no known data on the quality, efficacy, and safety of the Russian vaccine." a health ministry spokeswoman told German newspaper network RND.
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "Representational image")
)
)
)
)
)
)
)
)
)
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}